Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder
Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhé HG, Schene AH
Translational psychiatry · 210 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- ZonMw
- Universidad u hospital
- Universiteit van Amsterdam
- Gobierno
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Gobierno
- Dutch Research Council (NWO)
- Subvenciones
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (016.126.059;); ZonMw (016.126.059)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2016-03-15 · Transl Psychiatry · vol. 6 · número 3 · pág. e756
- Editorial
- Springer Nature
- Citado
- 282 citas · más que el 100% de estudios similares · 28.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 60 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Fatty Acid Research and Health · Diet and metabolism studies · Alcoholism and Thiamine Deficiency
- Palabras clave
- Major depressive disorder, Meta-analysis, Eicosapentaenoic acid, Internal medicine, Polyunsaturated fatty acid, Docosahexaenoic acid, Placebo, Antidepressant, Strictly standardized mean difference, Medicine, Psychiatry, Fatty acid, Biology, Pathology
- MeSH
- humans, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, antidepressive agents, regression analysis, depression, dietary supplements, randomized controlled trials as topic, major depressive disorder
6 autores
- Roel J. T. Mocking🇳🇱 · autor de correspondenciaAmsterdam UMC Location University of Amsterdam; University of Amsterdam
- Iris M Harmsen🇳🇱Amsterdam UMC Location University of Amsterdam; University of Amsterdam
- Johanna Assies🇳🇱Amsterdam UMC Location University of Amsterdam; University of Amsterdam
- Maarten W.J. Koeter🇳🇱Amsterdam UMC Location University of Amsterdam; University of Amsterdam
- Henricus Gerardus Ruhé🇳🇱University Medical Center Groningen; University of Groningen; Amsterdam UMC Location University of Amsterdam; University of Amsterdam
- Aart H. Schene🇳🇱Radboud University Nijmegen; Radboud University Medical Center; Donders Institute for Brain, Cognition and Behaviour
Resumen
El texto original del estudio, en el idioma en que se publicó.
Omega-3 polyunsaturated fatty acid (PUFA) supplementation has been proposed as (adjuvant) treatment for major depressive disorder (MDD). In the present meta-analysis, we pooled randomized placebo-controlled trials assessing the effects of omega-3 PUFA supplementation on depressive symptoms in MDD. Moreover, we performed meta-regression to test whether supplementation effects depended on eicosapentaenoic acid (EPA) or docosahexaenoic acid dose, their ratio, study duration, participants' age, percentage antidepressant users, baseline MDD symptom severity, publication year and study quality. To limit heterogeneity, we only included studies in adult patients with MDD assessed using standardized clinical interviews, and excluded studies that specifically studied perinatal/perimenopausal or comorbid MDD. Our PubMED/EMBASE search resulted in 1955 articles, from which we included 13 studies providing 1233 participants. After taking potential publication bias into account, meta-analysis showed an overall beneficial effect of omega-3 PUFAs on depressive symptoms in MDD (standardized mean difference=0.398 (0.114-0.682), P=0.006, random-effects model). As an explanation for significant heterogeneity (I(2)=73.36, P<0.001), meta-regression showed that higher EPA dose (β=0.00037 (0.00009-0.00065), P=0.009), higher percentage antidepressant users (β=0.0058 (0.00017-0.01144), P=0.044) and earlier publication year (β=-0.0735 (-0.143 to 0.004), P=0.04) were significantly associated with better outcome for PUFA supplementation. Additional sensitivity analyses were performed. In conclusion, present meta-analysis suggested a beneficial overall effect of omega-3 PUFA supplementation in MDD patients, especially for higher doses of EPA and in participants taking antidepressants. Future precision medicine trials should establish whether possible interactions between EPA and antidepressants could provide targets to improve antidepressant response and its prediction. Furthermore, potential long-term biochemical side effects of high-dosed add-on EPA supplementation should be carefully monitored.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.